Latest Conference Articles

July 31st 2014, 2:32pm

International Lung Cancer Congress

Paul A. Bunn, Jr., MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses the pros and cons of having companion diagnostic tests in lung cancer.

July 31st 2014, 1:40pm

International Lung Cancer Congress

When the US Preventive Services Task Force (USPSTF) recommended last year that asymptomatic, high-risk individuals should receive annual screening for lung cancer with low-dose computed tomography (LDCT), it made a healthy decision for the American population

July 31st 2014, 11:07am

International Lung Cancer Congress

James L. Mulshine, MD, professor, Associate Provost for Research, Vice President, Rush University Medical Center discusses new USPSTF recommendations for lung cancer screening.

July 31st 2014, 8:03am

International Lung Cancer Congress

Five novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial

July 31st 2014, 6:19am

International Lung Cancer Congress

The 15th Annual International Lung Cancer Congress, which began today in Huntington Beach, California and will continue through Saturday, will offer an array of information presented by multidisciplinary experts-in a brand-new format.

July 19th 2014, 12:39pm

International Congress on the Future of Breast Cancer West

Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses mechanisms of resistance to endocrine therapy.

July 18th 2014, 3:05pm

International Congress on the Future of Breast Cancer West

Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

July 17th 2014, 1:53pm

International Congress on the Future of Breast Cancer West

Joyce A. O'Shaughnessy, MD, discusses the evolving area of breast cancer subtype-specific cytotoxic agents.

June 30th 2014, 11:19am

ESMO Gastrointestinal Cancers Congress

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

June 28th 2014, 3:02pm

Multinational Association of Supportive Care in Cancer International Symposium

Aprepitant is significantly more effective than a comparator placebo-added regimen in preventing CINV in children, with benefits seen across all phases of treatment.

June 28th 2014, 12:43pm

ESMO Gastrointestinal Cancers Congress

A head-to-head comparison of cetuximab and bevacizumab in a phase III trial that was nearly 10 years in the making showed equivalence for chemotherapy plus either agent in terms of OS, PFS, and response rates for patients with certain previously untreated metastatic colorectal cancers.

June 28th 2014, 12:07pm

Multinational Association of Supportive Care in Cancer International Symposium

Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline with placebo in patients with non-small cell lung cancer.

June 28th 2014, 11:49am

ESMO Gastrointestinal Cancers Congress

Initial treatment with surgical resection of the primary tumor followed by systemic treatment yielded a 4.7-month OS benefit compared with the same treatments administered in the reverse order in patients with mCRC receiving palliative care.

June 28th 2014, 10:31am

ESMO Gastrointestinal Cancers Congress

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses a randomized phase III placebo-controlled trial that explored apatinib as a treatment for patients with advanced gastric cancer.

June 28th 2014, 10:17am

ESMO Gastrointestinal Cancers Congress

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial on the targeted therapies administered in colorectal cancer.

June 28th 2014, 10:08am

ESMO Gastrointestinal Cancers Congress

Treatment with the oral nucleoside TAS-102 significantly extended OS and PFS for patients with metastatic colorectal cancer refractory to standard therapies.

June 28th 2014, 8:41am

Multinational Association of Supportive Care in Cancer International Symposium

A single oral dose of rolapitant was found to be effective, safe, and long-lasting for the prevention of CINV in patients whose cancer was being treated with either highly or moderately emetogenic chemotherapy.

June 28th 2014, 8:33am

ESMO Gastrointestinal Cancers Congress

Andrea Wang-Gillam, MD, PhD, from the Siteman Cancer Center, discusses the trial design and results of the phase III NAPOLI-1 trial that examined MM-398 with 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer following progression on gemcitabine-based therapy.

June 28th 2014, 7:00am

ESMO Gastrointestinal Cancers Congress

Two active maintenance regimens following disease stabilization with standard induction therapy demonstrated superior disease-free outcomes compared with no treatment in patients with metastatic colorectal cancer.

June 28th 2014, 5:57am

Multinational Association of Supportive Care in Cancer International Symposium

Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based moderately emetogenic chemotherapy when compared with a longer duration of dexamethasone.